Kornimate/medical-research-clean huggingface dataset:
a study of clofarabine for older patients with newly diagnosed acute myelogenous leukemia (aml) (classic ii)

Conditions: Acute Myelogenous Leukemia; Acute Myeloid Leukemia

Summary: clolar (clofarabine injection) is approved by the food and drug administration (fda) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (all) who have had at least 2 prior treatment regimens. this study will evaluate the efficacy of clofarabine in elderly patients with acute myelogenous leukemia (aml) who are unlikely to benefit from treatment with intensive chemotherapy regimens (cytarabine and anthracycline based regimens) used in younger patients with aml.


Eligibility criteria:
inclusion criteria: * diagnosis of aml (de novo, secondary or with an antecedent hematologic disorder \[ahd\]) * age ≥ 60 years * eastern cooperative oncology group (ecog) performance status 0-2 * presence of at least one adverse prognostic factor: age ≥ 70 years; or ahd; or ecog performance status of 2; or intermediate or unfavorable (i.e., adverse) karyotype defined as any cytogenetic profile except the presence of any of the following: * t(8;21)(q22;q22) * inv(16)(p13;q22 or t(16;16)(p13;q22) * t(15;17)(q22;q12) and variants. * adequate renal and hepatic function: total bilirubin ≤ 1.5 x upper limit of normal (uln); aspartate aminotransferase (ast) and alanine aminotransferase (alt) ≤ 2.5 x uln; and serum creatinine ≤ 1.0 mg/dl; if serum creatinine \> 1.0 mg/dl, then the estimated glomerular filtration rate (gfr) must be \> 60 ml/min/1.73 m\^2 as calculated by the modification of diet in renal disease (mdrd) equation * adequate cardiac function: left ventricular ejection fraction (lvef) ≥ 40% or left ventricular fractional shortening ≥ 22% exclusion criteria: * diagnosis of acute promyelocytic leukemia * prior treatment with clofarabine * prior treatment for aml or an antecedent hematologic disorder * prior hematopoietic stem cell transplant (hsct) * prior radiation therapy to the pelvis * investigational agent received within 30 days prior to the first dose of study drug * ongoing uncontrolled systemic infection * diagnosis of another malignancy, unless the patient has been disease-free for at least 5 years following the completion of curative intent therapy with the following exceptions: patients with treated non-melanoma skin cancer, in-situ carcinoma or cervical intraepithelial neoplasia regardless of disease-free duration are eligible for this study if definitive treatment for the condition has been completed; patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on psa value are eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed * clinical evidence of central nervous system (cns) involvement * severe concurrent medical condition or psychiatric disorder that would preclude study participation * positive human immunodeficiency virus (hiv) test

Keywords: acute myelogenous leukemia acute myeloid leukemia newly diagnosed aml clofarabine classic ii clo243
study of xl999 in patients with non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: this clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of xl999 when given weekly to patients with non-small cell lung cancer (nsclc). xl999 is a small molecule inhibitor of multiple kinases including vegfr, pdgfr, fgfr, flt-3, and src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.


Eligibility criteria:
inclusion criteria: * males and females with histologically confirmed nsclc * prior treatment with a platinum- or taxane containing regimen * stage iiib with malignant effusion, stage iv or recurrent nsclc that is not amenable to curative therapy (either surgery or radiation therapy) * measurable disease according to response criteria for solid tumors (recist) * ecog performance status of 0 or 1 * life expectancy ≥3 months * adequate organ and marrow function * no other malignancies within 5 years * signed informed consent exclusion criteria: * radiation to ≥25% of bone marrow within 30 days of xl999 treatment * use of any systemic anticancer therapy within 30 days of xl999 treatment * more than 2 prior systemic cytotoxic chemotherapy regimens * more than 1 prior agent targeted against vegf or egfr (eg, bevacizumab, erlotinib, or gefitinib) * subject has not recovered to ≤ grade 1 or to within 10% of baseline from adverse events due to other medications administered \>30 days before study enrollment * uncontrolled and/or intercurrent illness * history of or known brain metastases, current spinal cord compression, or carcinomatous meningitis * pregnant or breastfeeding females * known hiv
examining the relationship between burnout and career commitment of occupational therapists in skilled nursing facilities

Conditions: Burnout Among Occupational Therapists

Summary: a mixed methods cross-sectional survey was created for the proposed research questions. the survey is best for this research as it will indicate if occupational therapy practitioners (otps) are burnt out through the maslach burnout inventory - human services survey (mbi-hss) and will provide information on a direct link to otps' intention of leaving or otps\&#39; decreased perceived quality of treatment interventions. by having clear evidence of the linkage, qualitative research generates non-numerical data to develop a deeper understanding of why otps are leaving the profession. by utilizing online recruitment methods, this will allow otps easier access and easier ability to administer. participants will be recruited utilizing purposeful and snowball sampling techniques. participants will be recruited from employer emails, social media and alumni pages. data will be collected for approximately one month, giving participants time to participate and pass along the survey to other colleagues. the survey will be completed on an anonymous online platform for ease and convenience of participation. the survey is broken into four sections. before starting the survey, participants had to indicate that they acknowledge and accept the informed consent. if they deny the informed consent, the survey was be submitted without asking questions. section two contained the demographic data. section three contained the mbi-hss. section four included the non-standardized quantitative and qualitative questions related directly to the intention of leaving the profession and their perceived quality of treatment interventions. burnout is a topic that will always be around and talked about. in order to gain a better understanding of the role that burnout plays in the field of occupational therapy and the direct effects if has on therapists and the profession is important. finding out the effects can help companies and the american occupational therapy association address these issues and adjust to the current needs.


Eligibility criteria:
inclusion criteria: * occupational therapists or certified occupational therapy assistants currently working in skilled nursing facilities or have worked in the last 2 years any age range, any state must have an active ot or cota license exclusion criteria: * ot or cota in a field other than skilled nursing facilities
analysis of clinical and molecular genetic data influencing the evolution and response to therapy of adpkd patients (autosomal dominant polycystic kidney disease)

Conditions: Autosomal Dominant Polycystic Kidney Disease

Summary: genkyst is a regional cohort involving up to nephrologists working in private and public nephrology centers in the west of france. it registers clinical and molecular genetic data of all consenting patients with adpkd from this area.


Eligibility criteria:
inclusion criteria: * adpkd patients followed in nephrology centers in the west of france * age \>17 exclusion criteria: * none

Keywords: polycystic disease
cognitive function and brain connectivity in cas patients:a rs-fmri study

Conditions: MRI, Functional; Carotid Artery Stenosis

Summary: this is a prospective study aimed to explore the changes of cognitive function after surgery for cas and the correlation with brain connectivity, in order to look for the clinical biomarkers to predict the carotid stent implantation for patients which can effect the cognition

carotid artery stenting (cas) can significantly decrease the incidence of ischemic stroke in patients with severe carotid artery stenosis has been confirmed in large randomized controlled studies (1, 2).previous studies showed carotid artery stenosis is closely related to cognitive dysfunction, including asymptomatic carotid artery stenosis(≥70%).cognitive impairment is one of the most serious problem facing the elderly. the impact on cognitive function in patients with cas has been discussed by many researchers, however the effect still remained conflicting. in past few years, several imaging techniques, such as resting-state functional mri (r-fmri), had been increasingly used to study cognitive impairment in humans. in this study, we evaluated the cognition performance in severe carotid artery stenosis patients undergoing cas and explored the mechanisms underlying the cognition changes by the rs-fmri. inclusion criteria: * age between 55 years and 80 years * unilateral internal carotid artery stenotic degree ≥ 70% * right-hand-dominant * free of dementia, and depression * modified rankin scale: 0 or 1 * education ≥6 years * obtained written informed consent. exclusion criteria: * contralateral internal carotid artery stenosis ≥ 50% * posterior circulation diseases * mmse \< 26, which is a cut-off value for mild cognitive impairment * severe systemic diseases and neuropsychiatric diseases (such as congestive heart failure) * any contraindications for mri scan (e.g., metal implants) * non atherosclerotic stenosis, such as dissection, vasculitis.

Eligibility criteria:
inclusion criteria: * age between 55 years and 80 years * unilateral internal carotid artery stenotic degree ≥ 70% * right-hand-dominant * free of stroke, tia, dementia, and depression * modified rankin scale: 0 or 1 * education ≥6 years * obtained written informed consent. exclusion criteria: * contralateral internal carotid artery stenosis ≥ 50% * posterior circulation diseases * mmse \< 26, which is a cut-off value for mild cognitive impairment * severe systemic diseases and neuropsychiatric diseases (such as congestive heart failure and history of stroke) * any contraindications for mri scan (e.g., metal implants)

Keywords: resting state mri carotid artery stenting cognition
study of psychiatric aspects in women with lower urinary tract symptoms

Conditions: Psychiatric Aspects in Women With Lower Urinary Tract Symptoms

Summary: to identify the differences in psychopathology, personality traits among different female luts subtypes.


Eligibility criteria:
inclusion criteria: * all cases with lower urinary tract symptoms exclusion criteria: * nil
the perioperative pain self-management program trial

Conditions: Postoperative Pain

Summary: this study will trial the impact of teaching surgical patients a pain self-management approach to compliment medical post-surgical pain management.

surgery can precipitate the development of both chronic pain and long-term opioid use. there is a need for strategies to augment perioperative pharmacotherapeutic management of pain with non-pharmacologic strategies to prevent long-term sequelae. psychological interventions such as cognitive behavioral therapy (cbt) can effectively reduce distress and improve functioning among patients with chronic pain. while cbt has been used extensively in patients with established chronic pain, it has not been used as a preventive intervention targeting the transition from acute to chronic postsurgical pain. the perioperative pain self-management (peps) program has the potential to reduce the incidence of chronic post-surgical pain and long-term opioid use among veterans. this study will: examine the efficacy of peps compared to standard care on 6-month pain (primary outcome), mood and functioning outcomes as well as time to post-surgical opioid and other analgesic use cessation.

Eligibility criteria:
inclusion criteria: * scheduled for total hip, knee, or shoulder joint arthroplasty through the iowa city, ia, des moines, ia, minneapolis, ia, or milwaukee wi, va medical centers exclusion criteria: * inability to complete study forms/procedures because of a language/literacy barrier * active bipolar or psychotic disorder * history of brain injury * dementia * cbt therapy within the past year * lack of access to a telephone for peps sessions

Keywords: postoperative pain opioid
a 2-month safety follow-up trial

Conditions: Type 1 Diabetes; Type 2 Diabetes

Summary: the main purpose of the trial is to evaluate pulmonary function in subjects who had completed any one of the 4 mkc parent trials (mkc-ti-009, mkc-ti-102, mkc-ti-103, or mkc-ti-030) for an additional 2-month safety follow-up.

this was a 2-month safety follow-up study of subjects from mannkind protocols mkc-ti-009, mkc-ti-102, mkc-ti-103 and mkc-ti-030. no study medications were administered during this trial. the adverse event data included are for the combined safety population irrespective of previous treatments in the parent trials.

Eligibility criteria:
inclusion criteria: * subjects who have completed any of the 4 mkc parent trials (mkc-ti-103, mkc-ti-009, mkc-ti-102, mkc-ti-030) * urine cotinine test of less than or equal to 100 ng/ml * written informed consent exclusion criteria: * subjects who started smoking during the 4 week follow-up phase of the parent trial * subjects who began a new inhaled insulin regimen with an investigational drug during the 4 week follow-up phase of the parent trial and/or are participation in another clinical trial * female subjects who are pregnant, lactating or planning on becoming pregnant * subjects with a positive urine drug screening at visit 1 * female subjects of child-bearing potential not practicing adequate birth control
hormonal management of heavy menstrual bleeding in adolescents

Conditions: Heavy Menstrual Bleeding; Bleeding Disorder

Summary: the goal of this study is to evaluate whether hormonal medications (such as contraceptive pill, patch, injectable progestins and hormonal intra-uterine device) have similar efficacy at managing heavy menstrual bleeding in adolescents with a bleeding disorder compared to those without. we also aim to assess the quality of life and hemoglobin and iron levels in this population.

adolescents with heavy menstrual bleeding and willing to start a hormonal medication to reduce menstrual flow are included. at baseline and during the study period, questionnaires and blood tests are performed. adolescents with a bleeding disorder are compared to those without. follow-up is 1 year.

Eligibility criteria:
inclusion criteria: * adolescents and young adults aged \< 26yo * presenting to the gynecology consultation at hug * diagnosed with heavy menstrual bleeding (pbac \> 100) * willing to initiate a hormonal medication to manage heavy menstrual bleeding exclusion criteria: * pregnancy or planning to become pregnant during the study period * already using hormonal medication for menstrual management and/or contraception * known anatomical uterine pathology * using anticoagulant or antiaggregant agents

Keywords: heavy menstrual bleeding bleeding disorder adolescent contraception menstrual management
pulmonary disease in patients referred for coronary ct

Conditions: Coronary Artery Disease; Atheroscleroses; COPD; Respiratory Diseases

Summary: several studies show an association between chronic obstructive pulmonary disease (copd) and coronary artery disease (cad). besides risk factors such as smoking, both are associated with physical inactivity, advanced age and systemic inflammation the use of coronary computed tomography (cct) with multiple detectors is a diagnostic method for coronary disease, describing the anatomy and severity of arterial obstruction. one way of estimating the cardiovascular risk is coronary calcium score (ccs). due to the association between copd and cad, it is likely that many patients with ihd diagnosed by ct have reduced lung function. the aim of this observational study is to establish the correlation between the ccs and lung function. it will also correlate the presence of irreversible airway obstruction with significant coronary lesions. patients over 40 years referred to cct who agree to participate in the study will perform a spirometry with bronchodilator and collect a blood sample to measure serum markers of inflammation and cardiovascular risk (glycemia, lipid profile, c reactive protein (crp), tumor necrosis factor-alpha (tnf-alpha) and fibrinogen). the data will be compared in the general population and in subgroups: smokers, former smokers and nonsmokers. one year after the cct patients will be contacted by the investigators and accessed for emergency room visits, hospital admissions and fatal or nonfatal coronary or respiratory events. the investigators hypothesis is that reduced lung function is independently associated with elevated ccs and is, also a risk factor for increased hospital admission and coronary events. the concomitant assessment of lung function and ccs can contribute knowledge about the epidemiological association between pulmonary disease and cad. this can also add to evidence for the use of spirometry as a marker of cardiovascular risk.


Eligibility criteria:
inclusion criteria: * patients referred for coronary ct. * age greater than 40 years exclusion criteria: * history of myocardial revascularization (surgical or percutaneous) * cognitive-functional incapacity to perform spirometry * contraindication for administration of 400 mcg of albuterol * acute myocardial infarction or unstable angina within 2 weeks * angina pectoris class iii or iv according to the canadian cardiovascular society * heart failure new york heart association class iii or iv

Keywords: coronary disease copd spirometry coronary tomography
stimulating after recovery from traumatic brain injury

Conditions: TBI (Traumatic Brain Injury)

Summary: this is a preliminary, prospective interventional study to investigate the feasibility of using transcutaneous alternating current stimulation (tacs) after a traumatic brain injury (tbi) to improve cognitive function and decision-making.

all participants engaged in the study will participate once weekly for six weeks at hennepin healthcare systems, inc. (hhs). each participant will be randomized into the block design of sham or tacs during the first three appointments or the last three appointments. while participating, both the tacs will be applied in accordance with the manufacturer's suggested use. participants will complete computer-based tasks, while taking part in either the sham or tacs stimulation. the study is investigating the use of neuromodulation after traumatic brain injury (tbi) for improved cognitive function.

Eligibility criteria:
inclusion criteria: * adults 18 years and older * diagnosis of a mild to moderate tbi (gcs \> 8 on admission) * able to perform a computerized assessment * willing to attend all scheduled appointments * able to undergo the informed consent process healthy participants: * adults 18 years and older * able to perform a computerized assessment * willing to attend all scheduled appointments * able to undergo the informed consent process exclusion criteria: * open wound on scalp * severe tbi diagnosis or gcs of less than 8 on admission * non-english speaking * incarcerated * implanted defibrillator or pacemaker * visual impairment that hinders ability to complete computerized assessments healthy subject exclusion criteria: * less than 18 years of age * open wound on scalp * tbi diagnosis * non-english speaking * incarcerated * implanted defibrillator or pacemaker * visual impairment that hinders ability to complete computerized assessments
time limited eating in type 1 diabetes

Conditions: Type 1 Diabetes

Summary: this study is a randomized-control pilot study that aims to evaluate time limited eating (tle) in the pediatric t1d population, implemented within the first six months after diagnosis. this period is characterized by residual β-cell function, during which tle may have the ability to preserve and improve β-cell activity, indicated by increased c-peptide production. the investigators aim to assess the feasibility, acceptability, and safety of tle in the pediatric t1d population, as well as to investigate the impact of tle on β-cell function, insulin sensitivity, and glycemic control.

this will be a two-armed study with an intervention and control group. feasibility and acceptability will be assessed by using questionnaires. safety will be indicated by hypoglycemia occurrence. β-cell function and insulin sensitivity will be evaluated using mixed meal tolerance test with c-peptide and glucose levels. glycemic control will be indicated by continuous glucose monitor (cgm). block randomization will be utilized to ensure the groups are balanced in terms of bmi. the study period will be 9 weeks in duration, including a week-long run-in period and an 8-week intervention period. there will be two in-person study visits at week 0 and week 9. anthropometrics including weight, height, and pubertal status will be evaluated at these times. group 1- standard care (control) * includes a minimum 12-hour feeding window for 7 days per week * no caloric restriction will be used * will wear a continuous glucose monitor group 2 - tle (intervention) * includes an 8-hour feed/16-hour fast for 7 days per week * will be instructed to consume all of their calories in the afternoon/evening period * can consume non-caloric beverages (water, tea, coffee) during the fasting period * will wear a continuous glucose monitor * no caloric restriction will be used

Eligibility criteria:
inclusion criteria: * includes age of 12-25 years * t1d diagnosed within 6 months * at least one positive pancreatic antibody including glutamic acid decarboxylase (gad) antibody, islet tyrosine phosphatase 2 (ia2) antibody, or insulin antibody * can be on either insulin injections or insulin pump * can be of any bmi status * can speak any language exclusion criteria: * negative pancreatic antibodies * unwillingness to wear a cgm

Keywords: type 1 diabetes time limited eating β-cell
vitamin d among young adults: an intervention study using a mobile 'app'.

Conditions: Vitamin D Deficiency

Summary: the purpose of this study is to examine whether a behavioural intervention changes attitudes, knowledge, intake or blood levels of vitamin d in young adults. the hypothesis is that an educational component and use of a mobile smartphone 'app' will increase knowledge and/or intake of vitamin d.


Eligibility criteria:
inclusion criteria: * men or women aged 18-25 years * must be fluent in english * must be currently living in canada * must own iphone, ipad or ipod touch running ios 7.0 or higher (handheld 'app' used in intervention is only available in apple store; not available for android or blackberry platforms at this time) exclusion criteria: * outside age group * not fluent in english * not living in canada * does not own the specified apple device

Keywords: vitamin d intervention behaviour mobile app